8-K: Nordicus Partners Corporation Acquires Remaining Stake in Orocidin A/S, Completing Full Ownership

Nordicus Partners Corporation has acquired the remaining 5.34% of Orocidin A/S, making it a wholly-owned subsidiary through a stock-based transaction.

Summary

• Nordicus Partners Corporation finalized the acquisition of the remaining 5.34% of Orocidin A/S, a Danish biopharmaceutical company, on November 12, 2024.
• The acquisition was completed through a stock purchase agreement where Nordicus issued 200,000 restricted shares of its common stock to the sellers of Orocidin shares.
• This transaction resulted in Orocidin becoming a 100% owned subsidiary of Nordicus Partners Corporation.
• The initial acquisition of 95% of Orocidin occurred in May 2024.
• Nordicus also acquired 100% of Bio-Convert ApS in November 2024.

Sentiment

Score: 7

Explanation: The sentiment is positive due to the completion of the acquisition and the expansion of Nordicus' portfolio, but there are risks associated with the newly issued shares and the clinical stage of the acquired companies.

Positives

• Nordicus now has full control of Orocidin, which could streamline decision-making and strategic alignment.
• The acquisition was completed through a stock transaction, conserving cash for Nordicus.
• The acquisition expands Nordicus' portfolio in the biopharmaceutical sector.
• Orocidin is a clinical-stage company with potential for future growth in the periodontitis treatment market.

Negatives

• The 200,000 restricted shares issued to the sellers will dilute existing shareholders.
• The shares issued were not registered under the Securities Act of 1933 and are subject to transfer restrictions.

Risks

• The newly issued shares are subject to transfer restrictions and may not be sold without registration or an exemption.
• The success of Orocidin's clinical trials and market acceptance of its products are not guaranteed.
• The company's future performance is subject to various risks and uncertainties, including market competition and regulatory changes.
• The company is reliant on securing ongoing funding from its shareholders to capitalize the company until the completion of the Phase I trials of its Orocidin product.

Future Outlook

The company's future performance is subject to various risks and uncertainties, including market competition and regulatory changes. The company is reliant on securing ongoing funding from its shareholders to capitalize the company until the completion of the Phase I trials of its Orocidin product. The company assumes no obligation to update any forward-looking statements as a result of new information or future events or developments, except as required by law.

Management Comments

• Nordicus Partners Corporation specializes in providing Nordic and U.S. life sciences companies with the best possible conditions to establish themselves on the U.S. market.
• Nordicus core competencies lie in assisting Danish as well as other Nordic and U.S. companies in different areas of corporate finance activities, such as: businessand market development, growth strategies, attracting the right people, partners and capital for businesses and company acquisitions and sales.

Industry Context

This acquisition is part of Nordicus' strategy to expand its presence in the life sciences sector, particularly in the biopharmaceutical space. The company is focusing on acquiring and developing companies with innovative therapies, such as Orocidin's periodontitis treatment and Bio-Convert's oral leukoplakia treatment.

Comparison to Industry Standards

• The acquisition of a clinical-stage biopharmaceutical company is a common strategy for companies looking to expand their product pipeline and market reach.
• The use of stock-based transactions is also a common practice in the biotech industry, especially for smaller companies that may not have significant cash reserves.
• Compared to other acquisitions in the biotech sector, the size of this transaction is relatively small, reflecting the early stage of Orocidin's development.
• Other companies such as Amgen, Gilead, and Biogen often acquire smaller biotech companies to bolster their pipelines, but these deals are typically much larger in scale.

Stakeholder Impact

• Shareholders of Nordicus will experience dilution due to the issuance of new shares.
• Employees of Orocidin will become part of the Nordicus group.
• Customers of Orocidin may see changes in the future as the company is integrated into Nordicus.
• Suppliers and creditors of Orocidin will now be dealing with Nordicus.

Next Steps

• Nordicus will integrate Orocidin as a wholly-owned subsidiary.
• Nordicus will continue to develop Orocidin's periodontitis therapies.
• Nordicus will continue to develop Bio-Convert's oral leukoplakia therapies.

Key Dates

Keywords

acquisition, biopharmaceutical, Orocidin A/S, Nordicus Partners Corporation, stock purchase, periodontitis, clinical-stage, shares, subsidiary, Bio-Convert ApS